Literature DB >> 2915381

Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

B E Johansson1, D J Bucher, E D Kilbourne.   

Abstract

BALB/c mice immunized with graded doses of chromatographically purified hemagglutinin (HA) and neuraminidase (NA) antigens derived from A/Hong Kong/1/68 (H3N2) influenza virus demonstrated equivalent responses when HA-specific and NA-specific serum antibodies were measured by enzyme-linked immunosorbent assays (ELISAs). Antibody responses measured by hemagglutination inhibition or neuraminidase inhibition titrations showed similar kinetic patterns, except for more rapid decline in hemagglutination inhibition antibody. Injection of mice with either purified HA or NA resulted in immunity manifested by reduction in pulmonary virus following challenge with virus containing homologous antigens. However, the nature of the immunity induced by the two antigens differed markedly. While HA immunization with all but the lowest doses of antigen prevented manifest infection, immunization with NA was infection-permissive at all antigen doses, although reduction in pulmonary virus was proportional to the amount of antigen administered. The immunizing but infection-permissive effect of NA immunization over a wide range of doses is in accord with results of earlier studies with mice in which single doses of NA and antigenically hybrid viruses were used. The demonstrable immunogenicity of highly purified NA as a single glycoprotein without adjuvant offers a novel infection-permissive approach with potentially low toxicity for human immunization against influenza virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2915381      PMCID: PMC247820          DOI: 10.1128/JVI.63.3.1239-1246.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

3.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

4.  Dependence of the activity of an influenza virus neuraminidase upon Ca2+.

Authors:  N J Dimmock
Journal:  J Gen Virol       Date:  1971-12       Impact factor: 3.891

5.  Selective induction of delayed hypersensitivity by a lipid conjugated protein antigen which is localized in thymus dependent lymphoid tissue.

Authors:  J Coon; R Hunter
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

6.  Comparative amino acid analysis of influenza A viral proteins.

Authors:  A H Erickson; E D Kilbourne
Journal:  Virology       Date:  1980-01-15       Impact factor: 3.616

7.  Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.

Authors:  E D Kilbourne
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

8.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

9.  Cell-mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans.

Authors:  T C Chow; K R Beutner; P L Ogra
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

10.  Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.

Authors:  P L Ogra; T Chow; K R Beutner; E Rubi; J Strussenberg; S DeMello; C Rizzone
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

View more
  77 in total

1.  Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens.

Authors:  Robert Sealy; Sherri Surman; Julia L Hurwitz; Christopher Coleclough
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

4.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 5.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

6.  Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

Authors:  Frédéric Kendirgi; Nadezda E Yun; Nathaniel S Linde; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Harilyn McMicken; Yin Chen; Slobodan Paessler
Journal:  Hum Vaccin       Date:  2008-11-21

7.  Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Authors:  I V Alymova; S Kodihalli; E A Govorkova; B Fanget; C Gerdil; R G Webster
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 8.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

9.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

10.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.